Vol 26, No 2 (2021)
Research paper
Published online: 2021-03-08

open access

Page views 822
Article views/downloads 817
Get Citation

Connect on Social Media

Connect on Social Media

Dosimetric and clinical outcomes of CT based HRCTV delineation for HDR intracavitary brachytherapy in carcinoma cervix — a retrospective study

Anis Bandyopadhyay1, Arnab Kumar Ghosh1, Bappaditya Chhatui1, Dhiman Das
Rep Pract Oncol Radiother 2021;26(2):170-178.

Abstract

Background: Brachytherapy for carcinoma cervix has moved from Point A based planning to optimization of dose based on HR-CTV. Guidelines have been published by GEC ESTRO on HR-CTV delineation based on clinical gynecological examination and MR sequences. These have given significant clinical results in terms of local control. However, many centers around the country and worldwide still use CT based planning, which restricts HR-CTV delineation, as disease and cervix can rarely be differentiated on a planning CT. Various studies have been done to develop CT based contouring guidelines from the available data, but enough evidence is not available on the clinical outcome when treatment is optimized to HR-CTV contoured on CT images. The purpose of this study is to find out the relation between local control and dosimetry of HR-CTV as delineated on CT images.

Materials and methods: Patients of locally advanced carcinoma cervix treated radically with EBRT of 50 Gy in 25# and at least 4 cycles of concurrent weekly Cisplatin having a complete or partial response to EBRT were taken for study. All patients had  completed CT based Intracavitary brachytherapy to 21 Gy in 3# of 7 Gy per # with dose prescription at point A and optimizing dose to reduce bladder and rectal toxicity. Follow up data on locoregional recurrence was obtained. HR-CTV delineation was done retrospectively on the treatment plan following guidelines by Viswanathan et al. EQD2 doses for EBRT+BT were calculated for point A and HR-CTV D90. The dosimetric data to HR-CTV and to Point A were then compared with patients with locoregional control and with local recurrence.

Results: 48 patients were taken, all had squamous cell carcinoma. The median age was 48 years. 33.33% were stage IIA, the rest were stage IIB. Median follow-up was 30 months with 25% developing recurrence of the disease. HR-CTV D90 EQD2 dose was significantly higher in patients with locoregionally controlled disease than in patients with local recurrence (83.97 Gy10 vs. 77.96 Gy10, p = 0.002). Patients with HR-CTV D90 EQD2 dose greater than or equal to 79.75 Gy10 had better locoregional control than patients receiving dose less than 79.75 Gy10 (p = 0.015). Kaplan Meier plot for PFS showed significantly improved PFS for patients receiving HR-CTV D90 dose of at least 79.75 Gy10 (log-rank p-value = 0.007). Three year progression free survival was 87.1% in patients receiving HR-CTV D90 dose of at least 79.75 Gy10.

Conclusion: CT based HR -CTV volume delineation with the help of pre brachytherapy clinical diagrams and MRI imaging may be feasible in a select subgroup of patients with complete or near-complete response to external beam radiation.

Article available in PDF format

View PDF Download PDF file

References

  1. Srivastava AN, Misra JS, Srivastava S, et al. Cervical cancer screening in rural India: Status & current concepts. Indian J Med Res. 2018; 148(6): 687–696.
  2. Cho O, Chun M. Management for locally advanced cervical cancer: new trends and controversial issues. Radiat Oncol J. 2018; 36(4): 254–264.
  3. Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991; 20(4): 667–676.
  4. Chassagne D, Dutreix A, Almond P, et al. Report 38. J Int Comm Radiat Units Meas. 1985; 20(1): NP–NP.
  5. Srivastava A, Datta NR. Brachytherapy in cancer cervix: Time to move ahead from point A? World J Clin Oncol. 2014; 5(4): 764–774.
  6. Datta NR. From 'points' to 'profiles' in intracavitary brachytherapy of cervical cancer. Curr Opin Obstet Gynecol. 2005; 17(1): 35–41.
  7. Katz A, Eifel PJ. Quantification of intracavitary brachytherapy parameters and correlation with outcome in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000; 48(5): 1417–1425.
  8. Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2010; 76(1): 104–109.
  9. International Commission on Radiation Units and Measurements (ICRU) [Internet]. https://icru.org/content/reports/prescribing-recording-and-reporting-brachytherapy-for-cancer-of-the-cervix-report-no-89 (2019 Dec 23).
  10. Haie-Meder C, Pötter R, Van Limbergen E, et al. Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005; 74(3): 235–245.
  11. Pötter R, Haie-Meder C, Van Li, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006; 78(1): 67–77.
  12. Nag S, Cardenes H, Chang S, et al. Image-Guided Brachytherapy Working Group. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. Int J Radiat Oncol Biol Phys. 2004; 60(4): 1160–1172.
  13. Hellebust TP, Kirisits C, Berger D, et al. Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol. 2010; 96(2): 153–160.
  14. Dimopoulos JCA, Petrow P, Tanderup K, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol. 2012; 103(1): 113–122.
  15. Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016; 120(3): 428–433.
  16. Nomden CN, Pötter R, de Leeuw AAC, et al. EMBRACE Collaborative Group. Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiother Oncol. 2019; 134: 185–190.
  17. Viswanathan AN, Erickson B, Gaffney DK, et al. Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2014; 90(2): 320–328.
  18. Viswanathan AN, Dimopoulos J, Kirisits C, et al. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys. 2007; 68(2): 491–498.
  19. Murakami N, Kasamatsu T, Wakita A, et al. CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer. BMC Cancer. 2014; 14: 447.
  20. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019; 145(1): 129–135.
  21. Wachter-Gerstner N, Wachter S, Reinstadler E, et al. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial. Radiother Oncol. 2003; 68(1): 51–59.
  22. CT or MRI for Image-based Brachytherapy in Cervical Cancer. https://www.researchgate.net/publication/221846219_CT_or_MRI_for_Image-based_Brachytherapy_in_Cervical_Cancer (2020 Jan 2).
  23. Dimopoulos JCA, Schard G, Berger D, et al. Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. Int J Radiat Oncol Biol Phys. 2006; 64(5): 1380–1388.
  24. Serban M, Kirisits C, Pötter R, et al. EMBRACE Collaborative Group. Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy. Radiother Oncol. 2018; 129(3): 567–574.
  25. Pötter R, Georg P, Dimopoulos JCA, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011; 100(1): 116–123.
  26. Bandyopadhyay A, Basu P, Roy K, et al. Treatment of locally advanced carcinoma cervix with special emphasis on brachytherapy: A practice pattern survey among young radiation oncologist of India. South Asian J Cancer. 2018; 7(4): 231–235.
  27. Ohno T, Wakatsuki M, Toita T, et al. The Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group (JROSG). Recommendations for high-risk clinical target volume definition with computed tomography for three-dimensional image-guided brachytherapy in cervical cancer patients. J Radiat Res. 2017; 58(3): 341–350.
  28. Kawashima A, Isohashi F, Mabuchi S, et al. A 3-year follow-up study of radiotherapy using computed tomography-based image-guided brachytherapy for cervical cancer. J Radiat Res. 2019; 60(2): 264–269.
  29. Rijkmans EC, Nout RA, Rutten IH, et al. Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. Gynecol Oncol. 2014; 135(2): 231–238.
  30. Simpson D, Yashar CM, Kannan N, et al. CT and MRI-based Image Guided Brachytherapy for Cervical Cancer: A Multi-institutional Report. Int J Radiat Oncol Biol Phys. 2012; 84(3): S19.
  31. MRI-guided high-dose-rate intracavitary brachytherapy in cervical cancers at Tata Memorial Hospital: The initial clinical outcome — Brachytherapy. https://www.brachyjournal.com/article/S1538-4721(09)00030-0/abstract (2020 Jul 9).
  32. Kusada T, Toita T, Ariga T, et al. Computed tomography-based image-guided brachytherapy for cervical cancer: correlations between dose-volume parameters and clinical outcomes. J Radiat Res. 2018; 59(1): 67–76.



Reports of Practical Oncology and Radiotherapy